Table 15Estimates of number needed to treat or harm for tibolone from the LIFT trial

OutcomesRR (95% CI)TrialsPlacebo Rate (SE)*Number of Events Reduced/Increased (95% CI)Number Needed to Treat/Harm (95% CI)
Breast cancer reduced
 All breast cancer
 Invasive0.32 (0.13, 0.80)12.80 (0.66)10 (3, 17)105 (58, 302)
 Estrogen receptor +
Fractures reduced
 Vertebral0.55 (0.41, 0.74)119.60 (1.75)44 (25, 61)23 (16, 40)
 Nonvertebral0.74 (0.58, 0.93)126.30 (2.04)34 (8, 56)29 (17, 104)
Thromboembolic events increased§0.57 (0.19, 1.69)1
 Deep vein thrombosis
 Pulmonary embolus
Stroke increased2.19 (1.14, 4.23)11.90 (0.53)11 (1, 36)88 (25, 584)
Endometrial cancer
Cataracts
*

Per 1000 women-years.

Numbers of events reduced/increased are calculated by assuming 1000 women take tibolone for 5 years.

Numbers needed to treat/harm are calculated by assuming each woman takes tibolone for 5 years.

§

Includes deep vein thrombosis and pulmonary embolus.

Per 1000 women-years.

Numbers of events reduced/increased are calculated by assuming 1000 women take tibolone for 5 years.

Numbers needed to treat/harm are calculated by assuming each woman takes tibolone for 5 years.

Includes deep vein thrombosis and pulmonary embolus.

From: Summary and Discussion

Cover of Comparative Effectiveness of Medications To Reduce Risk of Primary Breast Cancer in Women
Comparative Effectiveness of Medications To Reduce Risk of Primary Breast Cancer in Women [Internet].
AHRQ Comparative Effectiveness Reviews, No. 17.
Nelson HD, Fu R, Humphrey L, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.